CN105832736A - Application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema - Google Patents
Application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema Download PDFInfo
- Publication number
- CN105832736A CN105832736A CN201610311618.9A CN201610311618A CN105832736A CN 105832736 A CN105832736 A CN 105832736A CN 201610311618 A CN201610311618 A CN 201610311618A CN 105832736 A CN105832736 A CN 105832736A
- Authority
- CN
- China
- Prior art keywords
- pqq
- garlicin
- spray
- powder
- pyrroloquinoline quinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema. The weight ratio of pyrroloquinoline quinine (PQQ) to allicin is (0.30-0.60):1. The application has the advantages that the functions of improving immunity, killing pathogenic bacteria and jointly conditioning skin nerves are achieved, side effects are hardly generated for patients, and the treatment effect is good.
Description
Technical field
The present invention relates to treat neurodermatitis, eczema drug world, especially a kind of pyrroloquinoline quinone (PQQ) is in treatment
Application in terms of neurodermatitis, eczema.
Background technology
Neurodermatitis and eczema are all relatively common chronic dermatosis；Recent years, neurodermatitis and eczema
Patient get more and more, trace it to its cause, mainly caused by following two factor: first, along with the fast development of society, people
The environment lived also there occurs huge change, the problem of air pollution is day by day serious, increasing dust, sulphuric acid, nitre
A large amount of imperceptible dry grit such as acid, organic hydrocarbon compounds swim aloft uniformly so that human body skin holds after infecting
It is easily generated inflammation；Second, then it is that the living standard of people is more and more higher, diet is increasingly focused on enjoyment and causes ignoring flat
Weighing apparatus, makes physical function be affected, then shows on skin；Eczema, belongs to relatively common being caused by multiple internal and external factor
Epidermis and the inflammatory dermatoses of high dermis, its feature is pruritus conscious, violent, and skin lesion pleomorphism is symmetrical, has and oozes
Go out tendency, the chronic course of disease, easy recurrent exerbation；The traditional Chinese medical science is construed to health and there are some pyretic toxicity, makes health produce and repels and sensitive anti-
Should.Neurodermatitis (neurodermatitis) is then a kind of limitation cutaneous nerve dysfunction dermatoses, clinical characters
For skin lichenization, plump coarse, acute pruritus, the course of disease is slow, and recurrent exerbation is not healed in constant year, rear easily recurrence.And suffer from
The immunity of the dermopathic patient of both be all on the low side under, therefore lack opposing various viruses, the pest resistance of antibacterial, sense
Just recovery from illness it is difficult to after having contaminated pathogenic bacterium；In order to improve the immunity of human body, and conditioning skin function of nervous system, cure patient's
Neurodermatitis and eczema, people have studied the medicine of a lot of association area, but it is preferable the most not develop effect
Medicine.
But, in once research, it has been found that, the pyrroloquinoline quinone (PQQ) extracted in Ganoderma (also becoming Ganoderma)
Have and improve immune function of human body comprehensively, can promote that in human body neural factor synthesizes, and nurses one's health various nervous system disease simultaneously；
But based on technological deficiency, the most do not find that pyrroloquinoline quinone (PQQ) is in terms for the treatment of the medicine of neurodermatitis, eczema
Application.
Summary of the invention
In order to overcome the problems referred to above, the present invention provides pyrroloquinoline quinone (PQQ) in treatment neurodermatitis, eczema to society
In application.
The technical scheme is that the pyrroloquinoline quinone (PQQ) application in terms for the treatment of neurodermatitis, eczema, its
In, pyrroloquinoline quinone (PQQ) is 0.30-0.60:1 with the weight ratio of garlicin.
As improvement of the present invention, described pyrroloquinoline quinone (PQQ) is 0.35-with the weight ratio of garlicin
0.55:1。
As improvement of the present invention, described pyrroloquinoline quinone (PQQ) is 0.40-with the weight ratio of garlicin
0.50:1.The dosage form of described compositions includes: powder, powder agent, capsule, spray or unguentum.
In the present invention, garlicin is a kind of broad spectrum antibiotic, has stronger antibacterial, antiinflammatory, lowering blood pressure and blood fat etc. many
Plant biological function；And pyrroloquinoline quinone (PQQ) is as the necessary factor of human developmental, the growth of human body cell can be stimulated, especially
It is human activin B cell, T cell, is allowed to produce antibody, improves the immunologic function of human body.Pyrroloquinoline quinone (PQQ) is so far
Till the mankind find the most potent bioactive substance, immune function of human body can be improved comprehensively.Due to the fact that dexterously
Pyrroloquinoline quinone (PQQ) and garlicin are applied in the disease treating neurodermatitis, eczema, described pyrroloquinoline quinone
(PQQ) cooperate with garlicin, while killing pathogenic bacterium, antiinflammatory, co-conditioning cutaneous nerve function, moreover it is possible to improve machine
Body immunity so that in the patient external present invention with pyrroloquinoline quinone (PQQ) and the medicine of garlicin after, Huan Zheti
In pathogenic bacterium be killed, inflammation disappears, simultaneously the immunity of patient can be greatly improved, cutaneous nerve functional rehabilitation normal,
The intrusion of other pathogenic bacterium can also be stoped, the neurodermatitis of patient, eczema thus can be made to fully recover, be effectively prevented multiple
Send out；Therefore, the present invention has while killing pathogenic bacterium, co-conditioning cutaneous nerve function, moreover it is possible to improve immunity, simultaneously
Patient is nearly free from side effect and eutherapeutic advantage.
Accompanying drawing explanation
Fig. 1 is the fabrication processing sketch of the garlicin liquid in the present invention.
Fig. 2 is the fabrication processing sketch of the ointment in the present invention for rubbing.
Fig. 3 is the fabrication processing sketch of the spray in the present invention for spraying.
Fig. 4 is the fabrication processing sketch of the powder for being watered immersion or hot compress in the present invention.
Detailed description of the invention
Pyrroloquinoline quinone (PQQ) treatment neurodermatitis, eczema in terms of application, wherein, pyrroloquinoline quinone (PQQ) with
The weight ratio of garlicin is 0.30-0.60:1.
In the present invention, further, described pyrroloquinoline quinone (PQQ) is 0.35-0.55 with the weight ratio of garlicin:
1。
In the present invention, further, described pyrroloquinoline quinone (PQQ) is 0.40-0.50 with the weight ratio of garlicin:
1.Described pyrroloquinoline quinone (PQQ) and garlicin make powder, powder agent, capsule, spray or unguentum jointly.
Embodiment 1
Wherein, pyrroloquinoline quinone (PQQ) is 0.30:1 with the weight ratio of garlicin.
Embodiment 2
Wherein, described pyrroloquinoline quinone (PQQ) is 0.35:1 with the weight ratio of garlicin.
Embodiment 3
Wherein, described pyrroloquinoline quinone (PQQ) is 0.40:1 with the weight ratio of garlicin.
Embodiment 4
Wherein, described pyrroloquinoline quinone (PQQ) is 0.50:1 with the weight ratio of garlicin.
Embodiment 5
Wherein, described pyrroloquinoline quinone (PQQ) is 0.55:1 with the weight ratio of garlicin.
Embodiment 6
Wherein, described pyrroloquinoline quinone (PQQ) is 0.60:1 with the weight ratio of garlicin.
Wherein, in the present invention, the pyrroloquinoline quinone (PQQ) used is obtained by biofermentation technique；Used
Garlicin be present in garlicin liquid, the garlicin liquid in the present invention be by following technique obtain obtained by:
(11), get the raw materials ready；Select the Bulbus Allii of high-quality, stalk, point lobe, stripping underwear, rinse with clear water, remove impurity and undesirable set of Bulbus Allii
Grain；
(12), broken, drying；With pulverizer, garlic tablet is processed into pasty state；
(13), enzymolysis；Under the conditions of 15 DEG C-35 DEG C, described Bulbus Allii is stuck with paste standing 8h-16h and carries out enzymolysis；
(14), distillation；Being stuck with paste by the Bulbus Allii obtained in step (13) and carry out rotating thin film vacuum distilling, the condition of distillation is 35 DEG C-65
DEG C, vacuum is 0.6-0.9MPa, rotating speed 80-300r/min, steam pressure 0.3MPa, obtains the profit containing garlicin and distillates
Thing；
(15), separate；In step (14), obtain profit distillation adds the pure edible oil of 0.1%-0.5%, then revolve
Flow separation, obtains garlicin liquid；After tested, the content of the garlicin in garlicin liquid is 80%.
One, by the garlicin liquid that obtained by above-mentioned technique in the present invention according to the garlicin in any of the above-described embodiment and
The weight ratio of pyrroloquinoline quinone (PQQ) according to following technique make for erasing ointment:
(111), the mixing of medicine；Pyrroloquinoline quinone (PQQ) is mixed with 0.3-0.6:1.25 weight ratio with garlicin liquid,
Obtain compositions；
(112), concentrate；Compositions is evaporated to the clear paste that relative density is 1.1-1.2；
(113), the preparation of substrate；The Borneolum Syntheticum of 2-3 times of the weight portion of another qinghuo reagent, sulfur, by Borneolum Syntheticum, sulfur crushing extremely
300-500 mesh, obtains Borneolum Syntheticum fine powder and sulfur fine powder respectively；
(114), cream is become；The Oleum sesami of 1.2 times of the weight portion of qinghuo reagent, heats 80-100 DEG C by Oleum sesami, adds the weight of clear paste
The Cera Flava of 8-12 times of part, is down to room temperature after stirring, add step (112) gained clear paste and step (113) gained Borneolum Syntheticum
Fine powder, sulfur fine powder, stir, ointment；
(115), packaging.
The present invention is utilized respectively garlicin and the pyrroloquinoline quinone of the weight ratio according to embodiment 1 to embodiment 6
(PQQ) make the ointment for erasing, be designated as embodiment 1 ointment, embodiment 2 ointment, embodiment 3 ointment, embodiment 4 medicine respectively
Cream, embodiment 5 ointment and embodiment 6 ointment, after tested, more as follows compared with control sample 1:
Test one is to testing two curative effect situation criterion: (1) is effective: pruritus disappears, and without pain, illing skin situation is improved,
Immunity improves, without recurrence in half a year；(2) effective: pruritus disappears substantially, and illing skin situation is improved substantially, without pain, two
Without recurrence in individual month；(3) invalid: pruritus, recurrent exerbation.
Patient selects:
Test one: for the treatment of eczema patients
Patient selects: select 140 eczema patients, 30 years old mean age.140 eczema patients are randomly divided into seven groups, often
Organizing 20 people, often group correspondence rubs control sample 1 and erasing embodiment 1 ointment respectively to embodiment 6 ointment.
Symptom before patient treatment: the universal symptom of 140 eczema patients is affected part violent pruritus pain, is dried and easy chap
Split, show as the eczema initial stage.
Erasing consumption:
For each person every day the ointment being used for erasing is rubbed in affected part 3 times, the most early, middle and late each the most once, will suffer from before erasing every time
Place's warm water cleaning, a course for the treatment of is 15 days, continuously three courses for the treatment of of erasing；After three courses for the treatment of, contrast effect is as shown in table 1 below:
Interpretation of result: when treating eczema patients, for initial stage patient, patient rubs control sample 1 efficiently individual quantity and only has 1,
Effective percentage is 5%；And patient's erasing utilizes embodiment 1 ointment in the present invention to the average effectiveness level of embodiment 6 ointment to be
98.3%, wherein the effective percentage of embodiment 3 ointment, embodiment 4 ointment, embodiment 5 ointment and embodiment 6 ointment reaches 100%, can
See, due to containing pyrroloquinoline quinone (PQQ) and garlicin in embodiment 1 ointment in the present invention to embodiment 6 ointment, garlicin with
Pyrroloquinoline quinone (PQQ) mutually synergy so that the ointment for erasing obtained in the present invention makes major part patient's
The clinical symptoms of eczema can be improved, and even takes a turn for the better, and without recurrent exerbation, good effect, cure rate is high；And embodiment 3 ointment is extremely
Pyrroloquinoline quinone (PQQ) in embodiment 6 ointment is in incremental trend with the weight ratio of garlicin, namely pyrroles
Quinoline quinone (PQQ) is the biggest with the weight ratio of garlicin, and effect is the best.
Test two: for the treatment of neurodermatitis patient
Patient selects: select 140 neurodermatitis patients, 30 years old mean age.By random for 140 neurodermatitis patients
Being divided into seven groups, often organize 20 people, often group correspondence rubs control sample 1 and embodiment 1 ointment respectively to embodiment 6 ointment.
Symptom before patient treatment: the universal symptom of 140 neurodermatitis patients is the affected part micro-pain of violent pruritus, locally
The circle of foxtail millet granular Semen phaseoli radiati size or the flat pimple of polygon occur, in color of the leather, light red or filbert, are dried, have desquamation in small, broken bits,
Show as the neurodermatitis initial stage.
Erasing consumption:
For each person every day the ointment being used for erasing is rubbed in affected part 3 times, the most early, middle and late each the most once, will suffer from before erasing every time
Place's warm water cleaning, a course for the treatment of is 15 days, continuously three courses for the treatment of of erasing；After three courses for the treatment of, contrast effect is as shown in table 2 below:
Interpretation of result: when treating neurodermatitis patient, it is 0 that patient rubs the efficiently individual quantity of control sample 1, and effective percentage is 0；
And it is 94.1% that patient rubs embodiment 1 ointment in the present invention to the average effectiveness level of embodiment 6 ointment, wherein embodiment 6 medicine
The effective percentage of cream reaches 100%, it is seen then that embodiment 1 ointment in the present invention to embodiment 6 ointment is due to containing pyrroloquinoline quinone
(PQQ) and garlicin, garlicin and pyrroloquinoline quinone (PQQ) mutually synergy so that in the present invention, obtained being used for is wiped
The ointment being coated with makes the clinical symptoms of the neurodermatitis of major part patient to improve, and even takes a turn for the better, and without recurrent exerbation, curative effect
Good, cure rate is high；And make a general survey of knowable to the curative effect of embodiment 1 ointment to embodiment 6 ointment, embodiment 1 ointment is to embodiment 6 medicine
The effective percentage of cream is increasing trend, and the weight ratio of pyrroloquinoline quinone (PQQ) and garlicin is also in increasing trend, because of
This, pyrroloquinoline quinone (PQQ) is the biggest with the weight ratio of garlicin, and effect is the best.
Two, the garlicin liquid present invention obtained by above-mentioned technique is according to the garlicin in any of the above-described embodiment and pyrrole
Cough up the weight ratio of quinoline quinone (PQQ) and make the spray for spraying according to following technique:
(211), the mixing of medicine；Pyrroloquinoline quinone (PQQ) is mixed with 0.3-0.6:1.25 weight ratio with garlicin liquid,
Obtain compositions；
(212), distillation；The compositions distillation that will obtain in step (211), collects distillate；
(213), sterilizing；By distillate sterilizing under the conditions of 115 DEG C-125 DEG C, sterilization time is 0.5h-1h；
(214), ingredients；Distillate after step (213) sterilizing is cooled to 25 DEG C-30 DEG C, takes weight portion 10-15 times of distillate
Purified water, the propellant of 2 times, by distillate, purified water and propellant mix, shake up formation spray；
(215), the process of spray bottle；Take spray bottle some, spray bottle is cleaned, be dried 10-60 DEG C of-100 DEG C of conditions
20min, then sterilizing 1.5-2h under the conditions of 100 DEG C, after be cooled to 25 DEG C-30 DEG C standby；
(216), fill；In gnotobasis, the spray formed in step (214) is filled to the spray after processing in step (215)
In mist bottle；
(217), leak detection；
(218), lettering, packaging；
The present invention is utilized respectively garlicin and pyrroloquinoline quinone (PQQ) system of the weight ratio according to embodiment 1 to embodiment 6
Become the spray for spraying, be designated as embodiment 1 spray, embodiment 2 spray, embodiment 3 spray, embodiment 4 respectively
Spray, embodiment 5 spray and embodiment 6 spray, after tested, more as follows compared with control sample 1:
Test three is to testing four curative effect situation criterion: (1) is effective: pruritus disappears, and without pain, form a scab in surface, affected part, skin
Situation is improved, and immunity improves, without recurrence in half a year；(2) effective: pruritus disappears substantially, and without pain, skin changes substantially
Kind, without recurrence in two months；(3) invalid: pruritus, recurrent exerbation.
Patient selects:
Test three: for the treatment of eczema patients
Patient selects: select 70 eczema patients, 70 30 years old eczema patients mean aves.By random for 70 eczema patients
It is divided into seven groups, often organizes 10 people, the often corresponding spray that spraying control sample 1 and embodiment 1 to embodiment 6 are respectively prepared respectively of group
Mist agent.
Spraying consumption:
Spraying 5-8ml spray is in affected part for each person every day, sprays in three times, and a course for the treatment of is 15 days, three courses for the treatment of of continuous spray；
After three courses for the treatment of, contrast effect is as shown in table 3 below:
| Group | Effective number (people) | Efficiently individual quantity (people) | Invalid number (people) | Effective percentage (%) |
| Control sample 2 | 0 | 1 | 9 | 10% |
| Embodiment 1 spray | 8 | 1 | 1 | 90% |
| Embodiment 2 spray | 7 | 2 | 1 | 90% |
| Embodiment 3 spray | 9 | 1 | 0 | 100 % |
| Embodiment 4 spray | 7 | 3 | 0 | 100 % |
| Embodiment 5 spray | 8 | 1 | 1 | 90% |
| Embodiment 6 spray | 7 | 3 | 0 | 100 % |
Interpretation of result: when treating eczema patients, patient sprays control sample 1 efficiently individual quantity and only has 1, and effective percentage is 10%；And
It is 95% that patient sprays embodiment 1 spray in the present invention to the average effectiveness level of embodiment 6 spray, and wherein embodiment 3 is sprayed
The effective percentage of mist agent, embodiment 4 spray and embodiment 6 spray reaches 100%, it is seen then that embodiment 1 spray in the present invention
To embodiment 6 spray owing to containing pyrroloquinoline quinone (PQQ) and garlicin, garlicin is mutual with pyrroloquinoline quinone (PQQ)
Synergy so that the spray for spraying obtained in the present invention makes major part patient, and eczema symptom can after spraying
Controlled, even disappeared, and without recurrence, good effect in half a year, cure rate is high.
Test four: for the treatment of neurodermatitis patient
Patient selects: select 70 neurodermatitis patients, 30 years old mean age.70 neurodermatitis patients are divided at random
Becoming seven groups, often organize 10 people, often group correspondence sprays control sample 1 and embodiment 1 spray respectively to embodiment 6 spray.
Spraying consumption:
Spraying 5-8ml spray is in affected part for each person every day, sprays in three times, and a course for the treatment of is 15 days, three courses for the treatment of of continuous spray；
After three courses for the treatment of, contrast effect is as shown in table 4 below:
| Group | Effective number (people) | Efficiently individual quantity (people) | Invalid number (people) | Effective percentage (%) |
| Control sample 2 | 0 | 1 | 9 | 10% |
| Embodiment 1 spray | 7 | 2 | 1 | 90% |
| Embodiment 2 spray | 8 | 2 | 0 | 100% |
| Embodiment 3 spray | 7 | 3 | 0 | 100 % |
| Embodiment 4 spray | 9 | 1 | 0 | 100 % |
| Embodiment 5 spray | 9 | 1 | 0 | 100% |
| Embodiment 6 spray | 7 | 2 | 1 | 90 % |
Interpretation of result: when treating neurodermatitis patient, patient sprays the efficiently individual quantity of control sample 1 and only has 1, effective percentage
It is 10%；And patient sprays embodiment 1 spray in the present invention to the average effectiveness level of embodiment 6 spray and is about 96.7%,
Wherein the effective percentage of embodiment 2 spray, embodiment 3 spray, embodiment 4 spray and embodiment 5 spray reaches 100%, can
Seeing, embodiment 1 spray in the present invention to embodiment 6 spray is due to containing pyrroloquinoline quinone (PQQ) and garlicin, Bulbus Allii
Element and pyrroloquinoline quinone (PQQ) mutually synergy so that the spray for spraying obtained in the present invention makes major part
Patient's neurodermatitis symptom after spraying can be controlled, and even disappears, and without recurrence, good effect, cure rate in half a year
High.
Three, the garlicin liquid present invention obtained by above-mentioned technique is according to the garlicin in any of the above-described embodiment and pyrrole
The weight ratio coughing up quinoline quinone (PQQ) is made for being watered immersion or the powder of hot compress according to following technique.
(311), the mixing of medicine；By pyrroloquinoline quinone (PQQ) with garlicin liquid with 0.3-0.6:1.25 weight ratio
Mixing, obtains compositions；
(312), concentrate, be dried；Compositions is evaporated to the paste that relative density is 1.1-1.2；Then combination it is dried to obtain
Thing powder.
(313), the preparation of substrate；Separately take the Borneolum Syntheticum of 5-15 times of weight portion of composition powder, take composition powder
The Pulvis Talci of 20-25 times of weight portion, is broken to Borneolum Syntheticum powder 300-500 mesh and obtains Borneolum Syntheticum fine powder；
(314), the preparation of powder；By composition powder, Borneolum Syntheticum fine powder and Pulvis Talci mix homogeneously, obtain powder；
(315), packaging.
The present invention is utilized respectively garlicin and the pyrroloquinoline quinone of the weight ratio according to embodiment 1 to embodiment 6
(PQQ) make for being watered immersion or the powder of hot compress, be designated as embodiment 1 powder respectively, embodiment 2 powder, embodiment 3 dissipate
Agent, embodiment 4 powder, embodiment 5 powder and embodiment 6 powder, after tested, more as follows compared with control sample 1:
Test five is to testing six curative effect situation criterion: (1) is effective: pruritus disappears, and without pain, forming a scab in surface, immunity carries
Height, without recurrence in half a year；(2) effective: pruritus disappears substantially, without pain, without recurrence in two months；(3) invalid: pruritus, instead
Recurrence is made.
Patient selects:
Test five: for the treatment of eczema patients
Patient selects: select 70 eczema patients, 30 years old mean age.70 eczema patients are randomly divided into seven groups, often group
10 people, often group correspondence uses control sample 2 respectively, and is watered immersion or hot compress trouble with embodiment 1 powder to embodiment 6 powder
Place.
Consumption:
Take powder 250-500g for each person every day, add boiling water 1000～1500 milliliters, stirring, dissolve, soak after putting room temperature or
Hot compress is in affected part, and 1 time on the one, continuous 3 days be a course for the treatment of, within after the course for the treatment of five days, carries out the next course for the treatment of, three treatments again
After journey, contrast effect is as shown in table 5 below:
| Group | Effective number (people) | Efficiently individual quantity (people) | Invalid number (people) | Effective percentage (%) |
| Control sample 3 | 0 | 0 | 10 | 0 |
| Embodiment 1 powder | 6 | 2 | 2 | 80% |
| Embodiment 2 powder | 7 | 1 | 2 | 80% |
| Embodiment 3 powder | 8 | 1 | 1 | 90 % |
| Embodiment 4 powder | 6 | 1 | 3 | 70 % |
| Embodiment 5 powder | 7 | 2 | 1 | 90% |
| Embodiment 6 powder | 7 | 3 | 0 | 100 % |
Interpretation of result: when treating eczema patients, patient is 0 by the efficiently individual quantity of immersion or hot compress control sample 2, the most just
It it is void in whole；And patient is by the average effective of embodiment 1 powder in immersion or the hot compress present invention to embodiment 6 powder
Rate is about 85%, and wherein the effective percentage of embodiment 6 powder reaches 100%, it is seen then that embodiment 1 powder in the present invention dissipates to embodiment 6
Due to containing pyrroloquinoline quinone (PQQ) and garlicin, garlicin and pyrroloquinoline quinone (PQQ) mutually synergy in agent so that this
The powder for immersion or hot compress obtained in invention makes major part patient soaking or can eliminate pain after hot compress, subtracts
Light eczema symptom, and without recurrence in 3 months.
Test six: for the treatment of neurodermatitis patient
Patient selects: select 70 neurodermatitis patients, 30 years old mean age.70 neurodermatitis patients are divided at random
Becoming seven groups, often organize 10 people, often group correspondence is watered immersion with control sample 2 and embodiment 1 powder to embodiment 6 powder respectively
Or hot compress is in affected part.
Consumption:
Take powder 250-500g for each person every day, add boiling water 1000～1500 milliliters, stirring, dissolve, soak after putting room temperature or
Hot compress is in affected part, and 1 time on the one, continuous 3 days be a course for the treatment of, within after the course for the treatment of five days, carries out the next course for the treatment of, three treatments again
After journey, contrast effect is as shown in table 6 below:
| Group | Effective number (people) | Efficiently individual quantity (people) | Invalid number (people) | Effective percentage (%) |
| Control sample 3 | 0 | 1 | 9 | 10% |
| Embodiment 1 powder | 8 | 2 | 0 | 100% |
| Embodiment 2 powder | 6 | 1 | 3 | 70% |
| Embodiment 3 powder | 7 | 2 | 1 | 90 % |
| Embodiment 4 powder | 7 | 1 | 2 | 80 % |
| Embodiment 5 powder | 8 | 1 | 1 | 90% |
| Embodiment 6 powder | 6 | 4 | 0 | 100 % |
Interpretation of result: when treating neurodermatitis patient, patient by the efficiently individual quantity of immersion or hot compress control sample 2 is
1, effective percentage is 10%；And patient soaks or embodiment 1 powder in the hot compress present invention is to the average effective of embodiment 6 powder
Rate is about 88.3%, and wherein the effective percentage of embodiment 6 powder reaches 100%, it is seen then that embodiment 1 powder in the present invention is to embodiment 6
Owing to containing pyrroloquinoline quinone (PQQ) and garlicin, garlicin and pyrroloquinoline quinone (PQQ) mutually synergy, making in powder
Obtain the powder being used for being watered immersion or hot compress obtained in the present invention make major part patient soaking or can face after hot compress
Bed symptom can be improved, and even takes a turn for the better, and without recurrent exerbation, good effect, cure rate is high.
Control sample 1 is a kind of external-applied ointment for treating dermatitis；Can buy on the market, joining of control sample 1
Fang Wei: Cortex Phellodendri 8-18 part Cutis Bufonis 7-16 part Pheretima 7-16 part Radix Angelicae Sinensis 4-16 part.
Control sample 2 is a kind of spray for treating dermatitis；Can buy on the market, the formula of control sample 2 is: Pi
Rake leaf 5-15 Borneolum Syntheticum 4-14 part Radix Sophorae Flavescentis 2-8 part.
Control sample 3 be a kind of for treat eczema, neurodermatitis for soak or the powder of hot compress；Can be in city
Buying on face, the formula of control sample 3 is: Rhizoma Pinelliae 2-13 part Pheretima 7-16 part.
Claims (4)
1. the pyrroloquinoline quinone (PQQ) application in terms for the treatment of neurodermatitis, eczema, wherein, pyrroloquinoline quinone (PQQ) is with big
The weight ratio of allicin is 0.30-0.60:1.
Application the most according to claim 1, it is characterised in that: described pyrroloquinoline quinone (PQQ) and the weight portion of garlicin
Ratio is 0.35-0.55:1.
Application the most according to claim 2, it is characterised in that: described pyrroloquinoline quinone (PQQ) and the weight portion of garlicin
Ratio is 0.40-0.50:1.
4. according to the application described in any one claim in claim 1-3, it is characterised in that: described pyrroloquinoline quinone
(PQQ) powder, powder agent, capsule, spray or unguentum are jointly made with garlicin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610311618.9A CN105832736A (en) | 2016-05-11 | 2016-05-11 | Application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610311618.9A CN105832736A (en) | 2016-05-11 | 2016-05-11 | Application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105832736A true CN105832736A (en) | 2016-08-10 |
Family
ID=56591624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610311618.9A Pending CN105832736A (en) | 2016-05-11 | 2016-05-11 | Application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105832736A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518522A (en) * | 2008-02-29 | 2009-09-02 | 昆明振华制药厂有限公司 | Allicin external preparation and prepration method thereof |
| US20140178316A1 (en) * | 2011-06-06 | 2014-06-26 | Us Cosmeceutechs, Llc | Skin treatments containing pyrroloquinoline quinone (pqq) esters and methods of preparation and use thereof |
-
2016
- 2016-05-11 CN CN201610311618.9A patent/CN105832736A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518522A (en) * | 2008-02-29 | 2009-09-02 | 昆明振华制药厂有限公司 | Allicin external preparation and prepration method thereof |
| US20140178316A1 (en) * | 2011-06-06 | 2014-06-26 | Us Cosmeceutechs, Llc | Skin treatments containing pyrroloquinoline quinone (pqq) esters and methods of preparation and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王桂臣: "谈谈抗真菌药物的合理应用", 《中国医疗前沿》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041113B (en) | Plant compound gel for treating acne and preparation method thereof | |
| CN108452275A (en) | It is a kind of to have effects that the composition, medicament and preparation method of relaxing tendons and activating collaterals | |
| CN102416023A (en) | Periplaneta Americana L. and gel externally applied medicinal composition and preparation method and use thereof in preparation of externally applied medicines for treating scalding | |
| CN104013878A (en) | Foot-bathing medicinal vinegar for quickly treating dermatophytosis and preparation method thereof | |
| CN109248240A (en) | Pharmaceutical composition and preparation method thereof for traumatic injury | |
| CN1171259A (en) | Chinese medicine for curing burn and traumatic wound and its production method | |
| CN105832736A (en) | Application of pyrroloquinoline quinine (PQQ) to treatment of neurodermatitis and eczema | |
| CN108261487B (en) | Analgesic Chinese medicinal composition and analgesic plaster and analgesic patch prepared from the same | |
| CN1327832A (en) | Exterior-applied ointment for treating dermatitis | |
| CH712713B1 (en) | Coffee enriched with maca and how it is made. | |
| CN108078868A (en) | A kind of antiallergic composition for skin care item | |
| CN100531781C (en) | Chinese medicine composition for removing wart nevus | |
| CN1078396A (en) | Medicine for treating dermatosis and manufacture method thereof | |
| CN102961487B (en) | Compound combination made from pure traditional Chinese medicines and used for treating henpox and preparation method of combination | |
| CN101361868B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| WO2016180119A1 (en) | Topical preparation and the use thereof in preparing drugs for treating lumbar disc herniation | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| Pitchon et al. | How history can help present research of new antimicrobial strategies: the case of cutaneous infections’ remedies containing metals from the Middle Age Arabic pharmacopeia | |
| CN109395050A (en) | Paediatrics external application massage the ointment formula, preparation method and application for treating diarrhea | |
| CN107890482A (en) | A kind of medicine for treating pruitus and its application | |
| CN102961457A (en) | Veterinary drug used for treating eczema of pet | |
| CN102973630B (en) | Traditional Chinese medicine combination and preparation method thereof | |
| CN114392310B (en) | Anti-inflammatory antipruritic skin-moistening traditional Chinese medicine external preparation and preparation method and application thereof | |
| CN109432255A (en) | Preparation method, fermenation raw liquid and the application of fermenation raw liquid | |
| CN107029158A (en) | A kind of compound Chinese herb external preparation for treating a rabbits mange |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |
|
| RJ01 | Rejection of invention patent application after publication |